JP2016518842A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518842A5
JP2016518842A5 JP2016512010A JP2016512010A JP2016518842A5 JP 2016518842 A5 JP2016518842 A5 JP 2016518842A5 JP 2016512010 A JP2016512010 A JP 2016512010A JP 2016512010 A JP2016512010 A JP 2016512010A JP 2016518842 A5 JP2016518842 A5 JP 2016518842A5
Authority
JP
Japan
Prior art keywords
nucleoside
genotype
deoxyribonucleoside
cet
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518842A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/036137 external-priority patent/WO2014179446A2/en
Publication of JP2016518842A publication Critical patent/JP2016518842A/ja
Publication of JP2016518842A5 publication Critical patent/JP2016518842A5/ja
Pending legal-status Critical Current

Links

JP2016512010A 2013-05-01 2014-04-30 マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法 Pending JP2016518842A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201361818432P 2013-05-01 2013-05-01
US61/818,432 2013-05-01
US201361822112P 2013-05-10 2013-05-10
US61/822,112 2013-05-10
US201361839550P 2013-06-26 2013-06-26
US61/839,550 2013-06-26
US201361895784P 2013-10-25 2013-10-25
US61/895,784 2013-10-25
US201361898704P 2013-11-01 2013-11-01
US61/898,704 2013-11-01
US201461927897P 2014-01-15 2014-01-15
US61/927,897 2014-01-15
PCT/US2014/036137 WO2014179446A2 (en) 2013-05-01 2014-04-30 Microrna compounds and methods for modulating mir-122

Publications (2)

Publication Number Publication Date
JP2016518842A JP2016518842A (ja) 2016-06-30
JP2016518842A5 true JP2016518842A5 (enExample) 2017-06-15

Family

ID=50928262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512010A Pending JP2016518842A (ja) 2013-05-01 2014-04-30 マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法

Country Status (15)

Country Link
US (6) US9309513B2 (enExample)
EP (1) EP2992095B1 (enExample)
JP (1) JP2016518842A (enExample)
KR (1) KR102214740B1 (enExample)
CN (1) CN105378080A (enExample)
AU (1) AU2014259954B2 (enExample)
CA (1) CA2908939C (enExample)
EA (1) EA034731B1 (enExample)
HK (1) HK1221256A1 (enExample)
IL (1) IL241957B (enExample)
MX (1) MX371093B (enExample)
NZ (1) NZ630890A (enExample)
SG (2) SG11201508925WA (enExample)
TW (1) TW201446791A (enExample)
WO (1) WO2014179446A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
JP6649248B2 (ja) 2013-05-01 2020-02-19 レグルス セラピューティクス インコーポレイテッド 細胞取り込みの向上のための化合物および方法
JP6396474B2 (ja) * 2013-09-16 2018-09-26 ベーリンゲ、イノベイション、アクチボラグＶａｅｌｉｎｇｅ Ｉｎｎｏｖａｔｉｏｎ Ａｂ 組立製品、及び当該組立製品を組み立てる方法
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
US20170312297A1 (en) * 2014-11-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long Acting Pharmaceutical Compositions For Hepatitis C
SG11201703646SA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Combination long acting compositions and methods for hepatitis c
HRP20241087T1 (hr) * 2015-11-06 2024-11-08 Ionis Pharmaceuticals, Inc. Konjugirani protusmisleni spojevi za upotrebu u terapiji
KR20250078597A (ko) 2015-11-06 2025-06-02 아이오니스 파마수티컬즈, 인코포레이티드 아포리포프로테인 (a) 발현 조정
MX2018009854A (es) 2016-03-07 2018-11-09 Arrowhead Pharmaceuticals Inc Ligandos dirigidos para compuestos terapeuticos.
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
CN109476637B (zh) 2016-06-21 2022-02-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
CN116832169A (zh) 2016-09-02 2023-10-03 箭头药业股份有限公司 靶向配体
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
JP7279081B2 (ja) * 2018-05-08 2023-05-22 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
US20220098581A1 (en) * 2018-07-20 2022-03-31 Regulus Therapeutics Inc. Methods for Oral Delivery of Oligonucleotides
CN112843084A (zh) * 2019-11-27 2021-05-28 中国人民解放军第四军医大学 MiR-122-5p在制备促进创伤愈合药物中的应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
MX2024003529A (es) * 2021-10-08 2024-04-01 Regulus Therapeutics Inc Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica.
AU2022360530A1 (en) * 2021-10-08 2024-03-28 Regulus Therapeutics Inc. Methods and compositions for avoiding off-target effects

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10503364A (ja) 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
JP2000501414A (ja) 1995-11-22 2000-02-08 ザ・ジョンズ・ホプキンス・ユニバーシティー 生体分子の細胞取り込みを高めるリガンド
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP2003511016A (ja) 1999-10-04 2003-03-25 エクシコン エ／エス オリゴヌクレオチドを補充する高親和性ｒｎアーゼｈの設計
US20020068709A1 (en) * 1999-12-23 2002-06-06 Henrik Orum Therapeutic uses of LNA-modified oligonucleotides
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2002043771A2 (en) 2000-12-01 2002-06-06 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
CN1344803A (zh) 2001-09-27 2002-04-17 吴昌 核酸靶分子选择及扩增方法
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
NZ548254A (en) 2003-12-23 2008-09-26 Santaris Pharma As Oligomeric compounds for the modulation of BCL-2
EP1768998A2 (en) 2004-04-27 2007-04-04 Alnylam Pharmaceuticals Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
PL1747023T5 (pl) 2004-05-04 2017-05-31 Univ Leland Stanford Junior Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych
AU2005330637B2 (en) 2004-08-04 2012-09-20 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
WO2006031461A2 (en) 2004-09-09 2006-03-23 Isis Pharmaceuticals, Inc. Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
EP1841867A1 (en) 2005-01-24 2007-10-10 Avaris AB COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007021896A2 (en) 2005-08-10 2007-02-22 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
JP5523705B2 (ja) * 2005-08-29 2014-06-18 レグルス・セラピューティクス・インコーポレイテッド Ｍｉｒ−１２２ａをモジュレートする使用方法
US20090203893A1 (en) 2005-08-29 2009-08-13 Regulus Therapeutics, Llc Antisense compounds having enhanced anti-microrna activity
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
PL2666859T3 (pl) 2006-04-03 2019-09-30 Roche Innovation Center Copenhagen A/S Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
EP2695608B1 (en) 2006-10-03 2016-11-23 Arbutus Biopharma Corporation Lipid containing formulations
WO2008132234A2 (en) 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
CN101796062B (zh) 2007-07-05 2014-07-30 Isis制药公司 6-双取代双环核酸类似物
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
US7737125B2 (en) 2007-11-26 2010-06-15 Enzon Pharamaceuticals, Inc. LNA antagonists targeting the androgen receptor
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US9132147B2 (en) 2008-12-31 2015-09-15 Roche Innovation Center Copenhagen Use of LNA ApoB antisense oligomers for the treatment of acute coronary syndromes
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EA022757B1 (ru) 2009-06-08 2016-02-29 Мираджен Терапьютикс МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
KR20120095397A (ko) 2009-10-16 2012-08-28 글락소 그룹 리미티드 Ｈｂｖ 안티센스 억제제
SG183374A1 (en) 2010-02-24 2012-09-27 Arrowhead Res Corp Compositions for targeted delivery of sirna
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011130458A2 (en) 2010-04-13 2011-10-20 John Rossi Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
AU2011302152B2 (en) * 2010-09-15 2015-06-11 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
CA2816155C (en) 2010-12-17 2020-10-27 Arrowhead Research Corporation Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
CA2822161C (en) 2010-12-29 2018-05-29 Philipp Hadwiger Small molecule conjugates for intracellular delivery of nucleic acids
SG194636A1 (en) * 2011-04-25 2013-12-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
EP2722388B1 (en) * 2011-06-16 2017-08-09 Nippon Steel & Sumikin Eco-Tech Corporation Nucleic acid probe for assaying nucleic acids
WO2012175733A1 (en) 2011-06-23 2012-12-27 Santaris Pharma A/S Hcv combination therapy
US20140213632A1 (en) 2011-06-30 2014-07-31 Stella Aps HCV Combination Therapy
KR20140064765A (ko) 2011-06-30 2014-05-28 스텔라 에이피에스 Hcv 조합 치료
US10023861B2 (en) * 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
JP2014533099A (ja) 2011-11-07 2014-12-11 ステラ・アンパルトセルスカブＳｔｅｌｌａ Ａｐｓ Ｈｃｖ＋患者におけるミクロｒｎａ−１２２阻害剤の有効性をチェックするための予測方法
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
DK3354734T3 (da) 2012-06-21 2020-06-29 Miragen Therapeutics Inc Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster
JP6352269B2 (ja) 2012-09-26 2018-07-04 ミルクス セラピューティクス アクティーゼルスカブＭｉｒｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａ／Ｓ オフターゲットプロファイルの改善されたオリゴマー
JP6452614B2 (ja) 2012-11-15 2019-01-16 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドコンジュゲート
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
DK2951305T3 (en) 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
PE20152002A1 (es) 2013-05-01 2016-01-21 Isis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de ttr y vhb
JP6649248B2 (ja) 2013-05-01 2020-02-19 レグルス セラピューティクス インコーポレイテッド 細胞取り込みの向上のための化合物および方法

Similar Documents

Publication Publication Date Title
JP2016518842A5 (enExample)
JP2016503800A5 (enExample)
Gentile et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir
CN102123716B (zh) 用于治疗病毒感染的化合物和方法
De Clercq Current race in the development of DAAs (direct-acting antivirals) against HCV
JP2015512860A5 (enExample)
US20060122154A1 (en) Thionucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20140369963A1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
JP2012519181A5 (enExample)
JP2013538560A5 (enExample)
Schinazi et al. HCV drug discovery aimed at viral eradication
JP2005533108A (ja) Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
JP2010514768A5 (enExample)
US20210040483A1 (en) Modified oligonucleotides and methods of use
JP2014520772A (ja) Ｈｃｖ併用療法
JP2010509376A5 (enExample)
JP2016518842A (ja) マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法
JP2009504157A5 (enExample)
JP2014503516A5 (enExample)
JP2014513954A5 (enExample)
EP3194401A1 (en) Solid forms of a toll-like receptor modulator
MX2011007194A (es) Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
RU2011139180A (ru) Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции
KR20120139699A (ko) Ｃ형 간염 바이러스 감염의 치료 요법
EA035301B1 (ru) 4'-фтор-2'-метилзамещенные нуклеозидные производные